U.S. lung transplant policy to be reviewed
U.S. officials will review the nation's lung transplant policy for children, but any change could take up to two years, not enough time to save the life of a 10-year-old Pennsylvania girl who's already been waiting 18 months for new lungs.
ConclusionFor details of pre/post processing, see Table. Since early 2017 we introduced chest/abdominal cavity wash with 1:1 saline-betadine mix and scrubbing T11-L4VB logs with chlora-prep that has eliminated bacterial contamination for the last 3 products. The first 2 were infused without adverse events following IRB/FDA approved antibiotic prophylaxis.Initially, processing of the VBs was arduous, using a scalpel and wire brush to clean the logs, then dissecting into small pieces with a mallet and osteotome. Since early 2017 a Stryker RemB saw has been used. A physical task that had taken 2 technologists 3 hours to compl...
African Americans (AA) have reduced survival compared to Caucasians after heart transplantation (HTx).
The purpose of this study is to evaluate the utility of vasoactive-inotropic score (VIS) in predicting outcomes after left ventricular assist device (LVAD) implantation and explore possible mechanisms of post-operative hemodynamic instability.
ConclusionsThis analysis defines center-level trends in lung transplantation after CMS flagging. Contrary to our primary hypothesis, flagging did not result in temporal center-level changes. However, programs on prolonged probation demonstrated reduced activity, which likely indicates a shift to higher performing centers.
ConclusionsSarcopenia was associated with poorer short-term outcome, and sarcopenic overweight with poorer overall survival of lung transplant patients.
In this study we describe 2 cases of successful adult DCD HT performed at our institution using an original protocol.
The continuous-flow centrifugal HeartMate 3 left ventricular assist device (Abbott, Abbott Park, IL) is associated with a low risk of de-novo pump thrombosis. In a previous study (the Minimal AnticoaGulation EvaluatioN To aUgment heMocompatibility [MAGENTUM-1] study, ClinicalTrials.gov No. NCT03078374; funded by Abbott and the Ministry of Health, Czech Republic), we reported results of a prospective, observational, pilot trial of reduced intensity warfarin (target international normalized ratio [INR] range 1.5 –1.9) with aspirin in 15 patients implanted with a HeartMate 3 pump and enrolled after 6 weeks.